Cellectar Biosciences (NASDAQ:CLRB) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. CLRB has been the subject of several other reports. LADENBURG THALM/SH SH started coverage on Cellectar Biosciences in a research report on Thursday, […]
More Stories
30-Year Treasury Yield Hits Highest Level in 19 Years
By Naveen Athrappully The U.S. 30-year Treasury yield is trading at levels last seen 19 years ago, near the onset...
No Peace Talks Taking Place With Iran, Trump Says
By Timothy Frudd President Donald Trump said on Aug. 18 that the United States was not holding negotiations with Iran...
Ukraine Launches 620 Drones at Moscow Region, as Russian Missile Attack Kills 10 in Ukraine
By Victoria Friedman Moscow and Kyiv have continued their aerial bombardments of each other, with Ukraine launching hundreds of unmanned...
What is the Entry-Level CCNA Salary? Registration Process, Tracking, and Job Roles
Confused about choosing CCNA as your profession? Curious to know about CCNA salary based on your experience and certifications? Don’t...
Why Businesses Choose Virtual Offices in NYC
Manhattan is one of the most expensive real estate markets in the world, and yet thousands of companies plant their...
What are the Three Goals of Cybersecurity? A Complete Guide on the CIA Triad
With the continuously moving environment, the need for cybersecurity has increased. Digital life is growing faster than ever. One weak...